Phase 3 Head-to-Head Trial Showed KYPROLIS ® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients

First-and-Only Head-to-Head Study Comparing Proteasome Inhibitors to Demonstrate Statistically Significant Improved Overall Survival Detailed Results Will be Presented at the 16th International Myeloma Workshop (IMW) in New Delhi THOUSAND OAKS, Calif., Feb. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myeloma treated with KYPROLIS® (carfilzomib) and dexamethasone (Kd) lived 7.6 months longer than those treated with Velcade® (bortezomib) and dexa...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news